Article Contents ::
- 1 The Brand Name JUBLIN Has Generic Salt :: PREGABALIN
- 2 JUBLIN Is From Company D.R.John’S Priced :: Rs. 70.80/125.00
- 3 JUBLIN have PREGABALIN is comes under Sub class Anti Epileptics of Main Class Nervous System
- 4 Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Epileptics
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name JUBLIN Has Generic Salt :: PREGABALIN
JUBLIN Is From Company D.R.John’S Priced :: Rs. 70.80/125.00
JUBLIN have PREGABALIN is comes under Sub class Anti Epileptics of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Epileptics
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Anxiety, Fibromyalgia, Post herpetic Neuralgia, Partial seizures, Pain from diabetic neuropathy, Neuropathic pain associated with spinal cord injury
Drug Dose ::
Oral Neuropathic pain Adult: Initially, 150 mg/day, may increase to 300 mg/day after 3-7 days. Max: 600 mg/day after a 7-day interval. All doses to be given in 2 or 3 divided doses. Adjunct in partial seizures Adult: Initially, 150 mg/day, may increase to 300 mg/day after a wk. Max: 600 mg/day. All doses to be given in 2 or 3 divided doses. Fibromyalgia Adult: Initially, 150 mg/day, may increase to 300 mg/day after a wk. Max: 450 mg/day, if needed. All doses to be given in 2 or 3 divided doses. Anxiety Adult: Initially, 150 mg/day, may increase in increments of 150 mg wkly. Max: 600 mg/day. All doses to be given in 2 or 3 divided doses. Post herpetic neuralgia Adult: Initially, 150-300 mg/day in divided doses. Max: 600 mg/day in divded doses. Renal impairment: Haemodialysis: 25-100 mg immediately after each 4-hr haemodialysis session. CrCl (ml/min) 30 to <60 75 mg/day. Max: 300 mg/day. All doses to be given in 2 or 3 divided doses. 15 to <30 Initially, 25-50 mg/day. Max: 150 mg/day. All doses to be given as a single dose or in 2 divided doses. <15 Initially, 25 mg/day. Max: 75 mg/day. All doses to be given as a single dose. Contraindication ::
Hypersensitivity. Pregnancy, lactation. Driving or working with machines, or do other dangerous activities.
Drug Precautions ::
Abrupt or rapid discontinuation of Pregabalin may produce some symptoms including insomnia, nausea, headache and diarrhoea. So Pregabalin should be tapered gradually over a minimum of 1 week rather than discontinued abruptly. Pregabalin treatment may associate with creatine kinase elevations. It should be discontinued if myopathy is diagnosed or suspected or if markedly elevated creatine kinase levels occur. Discontinue treatment if patients develop severe angioedema. Withdraw treatment gradually over at least 1 wk. May cause peripheral oedema. Regular vision check is recommended. May decrease platelet count and prolong PR interval.
Drug Side Effects ::
Dizziness, drowsiness, visual disturbance (including blurred vision, diplopia), ataxia, dysarthria, tremor, lethargy, memory impairment, euphoria, wt gain, constipation, dry mouth, peripheral edema, depression, confusion, agitation, hallucinations, myoclonus, hypoaesthesia, hyperaesthesia, tachycardia, excessive salivation, sweating, flushing, rash, muscle cramp, myalgia, arthralgia, urinary incontinence, dysuria, thrombocytopenia, neutropenia, 1st ° heart block, hypotension, hypertension, pancreatitis, dysphagia, oliguria, rhabdomyolysis.
Pregnancy category ::
Drug Mode of Action ::
Pregabalin is an analog of the neurotransmitter GABA. It binds potently to the ?2-? subunit resulting in modulation of Ca channels and reduction in the release of several neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, calcitonin gene-related peptide and substance P.
Drug Interactions ::
May potentiate the effects of lorazepam. Additive CNS depressant effects w/ opiates and benzodiazepines. May increase risk of angioedema w/ ACE inhibitors. May increase risk of wt gain and peripheral oedema w/ thiazolidinediones.